View in EDS

Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec‐butylpropylacetamide and its individual stereoisomers.

Saved in:
Bibliographic Details
Title: Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec‐butylpropylacetamide and its individual stereoisomers.
Authors: Erenburg, Natalia (AUTHOR), Hamed, Roa'a (AUTHOR), Nemirovski, Alina (AUTHOR), Bialer, Meir (AUTHOR), Eyal, Sara (AUTHOR)
Source: Epilepsia (Series 4). Sep2025, Vol. 66 Issue 9, p3544-3554. 11p.
Subjects: Valproic acid, Carrier proteins, Teratogenicity testing, Choriocarcinoma, Folic acid, Stereoisomers, Amide derivatives
Abstract: Objective: We have previously shown that valproic acid (VPA) alters the expression of placental carriers of essential nutrients, including folates. Here, we exposed a placental cell line to VPA, its central nervous system‐active amide derivative sec‐butylpropylacetamide (SPD), and its individual stereoisomers to address the question of whether folate carrier expression can predict the teratogenicity of VPA‐related compounds. We additionally conducted a pilot analysis of folate transfer across placental cell monolayers to estimate the translation of altered carrier expression to carrier activity. Methods: BeWo cells were incubated for 2 or 5 days with racemic SPD, its stereoisomers (2S,3S)‐SPD, (2R,3S)‐SPD, and (2R,3R)‐SPD (previously found to be teratogenic at high doses in mice;.5 or 1 mmol·L−1), VPA (1 mmol·L−1 = 144 mg/L), or their vehicle. Expression of FOLR1 (folate receptor alpha), SLC19A1 (reduced folate carrier), and ABCG2 (breast cancer resistance protein) was measured by real‐time polymerase chain reaction. Folate transfer across monolayers of BeWo b30 cells exposed to.5 mmol·L−1 (2R,3R)‐SPD or 1 mmol·L−1 VPA was quantified by liquid chromatography–mass spectrometry analysis. Results: At 1 mmol·L−1, racemic SPD, (2S,3S)‐SPD, and (2R,3S)‐SPD reduced by twofold SLC19A1 expression, similar to VPA (p <.001). SPD and its enantiomers induced FOLR1 expression by up to twofold (p <.05) or did not significantly affect it, and racemic SPD increased ABCG2 expression (p <.01). After 5 days, VPA, but not (2R,3R)‐SPD, enhanced both maternal‐to‐fetal and fetal‐to‐maternal folate transfer (p <.01), resulting in a 15% increase in net transfer in the fetal direction. Significance: Altered expression of the studied carriers could not explain the folate transfer kinetics across placental cell monolayers. Future studies should assess the effects of VPA and other antiseizure medications on transplacental transfer of essential compounds in vivo and the ability to predict it by functional in vitro assays. [ABSTRACT FROM AUTHOR]
Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Objective: We have previously shown that valproic acid (VPA) alters the expression of placental carriers of essential nutrients, including folates. Here, we exposed a placental cell line to VPA, its central nervous system‐active amide derivative sec‐butylpropylacetamide (SPD), and its individual stereoisomers to address the question of whether folate carrier expression can predict the teratogenicity of VPA‐related compounds. We additionally conducted a pilot analysis of folate transfer across placental cell monolayers to estimate the translation of altered carrier expression to carrier activity. Methods: BeWo cells were incubated for 2 or 5 days with racemic SPD, its stereoisomers (2S,3S)‐SPD, (2R,3S)‐SPD, and (2R,3R)‐SPD (previously found to be teratogenic at high doses in mice;.5 or 1 mmol·L−1), VPA (1 mmol·L−1 = 144 mg/L), or their vehicle. Expression of FOLR1 (folate receptor alpha), SLC19A1 (reduced folate carrier), and ABCG2 (breast cancer resistance protein) was measured by real‐time polymerase chain reaction. Folate transfer across monolayers of BeWo b30 cells exposed to.5 mmol·L−1 (2R,3R)‐SPD or 1 mmol·L−1 VPA was quantified by liquid chromatography–mass spectrometry analysis. Results: At 1 mmol·L−1, racemic SPD, (2S,3S)‐SPD, and (2R,3S)‐SPD reduced by twofold SLC19A1 expression, similar to VPA (p <.001). SPD and its enantiomers induced FOLR1 expression by up to twofold (p <.05) or did not significantly affect it, and racemic SPD increased ABCG2 expression (p <.01). After 5 days, VPA, but not (2R,3R)‐SPD, enhanced both maternal‐to‐fetal and fetal‐to‐maternal folate transfer (p <.01), resulting in a 15% increase in net transfer in the fetal direction. Significance: Altered expression of the studied carriers could not explain the folate transfer kinetics across placental cell monolayers. Future studies should assess the effects of VPA and other antiseizure medications on transplacental transfer of essential compounds in vivo and the ability to predict it by functional in vitro assays. [ABSTRACT FROM AUTHOR]
ISSN:00139580
DOI:10.1111/epi.18470